CN Patent

CN120829398A — 4-苯基-n-[(1s)-2-环丙基-1-苯基乙基]-5-甲基-n-丙-2-炔基-1,3-噻唑-2-胺类的合成方法

Assigned to Sanofi Aventis France · Expires 2025-10-24 · 1y expired

What this patent protects

本公开内容涉及化学和医药领域，更具体地涉及制备4‑(2‑氯‑4‑甲氧基‑5‑甲基苯基)‑N‑[(1S)‑2‑环丙基‑1‑(3‑氟‑4‑甲基苯基)乙基]‑5‑甲基‑N‑丙‑2‑炔基‑1,3‑噻唑‑2‑胺(化合物1)、其药学上可接受的盐和晶型的方法，用于治疗先天性肾上腺皮质增生症(CAH)的方法。

USPTO Abstract

本公开内容涉及化学和医药领域，更具体地涉及制备4‑(2‑氯‑4‑甲氧基‑5‑甲基苯基)‑N‑[(1S)‑2‑环丙基‑1‑(3‑氟‑4‑甲基苯基)乙基]‑5‑甲基‑N‑丙‑2‑炔基‑1,3‑噻唑‑2‑胺(化合物1)、其药学上可接受的盐和晶型的方法，用于治疗先天性肾上腺皮质增生症(CAH)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN120829398A
Jurisdiction
CN
Classification
—
Expires
2025-10-24
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Aventis France
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.